Global and Japan Congestive Heart Failure (CHF) Treatment Devices Market Insights, Forecast to 2027

Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.

Market Analysis and Insights: Global and Japan Congestive Heart Failure (CHF) Treatment Devices Market
This report focuses on global and Japan Congestive Heart Failure (CHF) Treatment Devices market.
In 2020, the global Congestive Heart Failure (CHF) Treatment Devices market size was US$ 4984.2 million and it is expected to reach US$ 6369.4 million by the end of 2027, with a CAGR of 3.1% during 2021-2027. In Japan the Congestive Heart Failure (CHF) Treatment Devices market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Congestive Heart Failure (CHF) Treatment Devices Scope and Market Size
Congestive Heart Failure (CHF) Treatment Devices market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Congestive Heart Failure (CHF) Treatment Devices market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Congestive Heart Failure (CHF) Treatment Devices market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
Cardiac Resynchronization Therapy (CRT)
Implantable Cardioverter Defibrillators (ICDs)

Segment by Application
Left Ventricular Assist Device (LVAD)
Right Ventricular Assist Device (RVAD)
Biventricular Assist Device (BIVAD)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Abiomed
Berlin Heart GmbH
Biotronik SE & Co. KG
Boston Scientific Corporation
HeartWare International
Jarvik Heart
LivaNova PLC
Medtronic
ReliantHeart
Abbott